OPIOIDS AND THE CHRONIC PAIN PATIENT: INDICATIONS, REFORMULATIONS AND REGULATIONS
1:00 pm - 3:30 pm, Astor Ballroom - 7th Floor
Course Code: SP-06
Speaker: RUSSELL K. PORTENOY, M.D.
Dr. Portenoy - Receives consultant fees from Ameritox, LTD, Cephalon, Inc., Grupo Ferrer Pharmaceutical, King Pharmaceuticals, Inc., Nicox, Pfizer Inc., Shire Pharmaceuticals, Solvy Pharmaceuticals, Wyeth and Xenon. The Department of Pain Medicine and Palliative Care receives funded research support from Archimedes Pharmaceuticals, Baxter International Inc., Calloway Labs, Cephalon, Inc., Endo Pharmaceuticals, Flamek Corporation, Fralex Therapeuticals Inc., GW Pharmaceuticals, King Pharcaceuticals, Inc., Pfizer Inc., Purdue Pharma L.P., Tempur-Pedic Management, United BioSource Corporation, Wyeth.
Objective(s):
Objective(s):
1. Determine which chronic pain patients are appropriate for opioid treatment and which are potential abusers;
2. Discuss the utility of abuse deterrent formulations;
3. Describe opioid-induced hyperalgesia and tolerance and its effect on patient care.
1. How To Decide Which Patient Is Suitable For Prolonged Opiate Therapy
2. Am I Going To Get in Trouble Prescribing All These Opioids
3. How Will Abuse Deterrent Formulations Affect My Practice
4. Latest On Opiate Induced Hyperalgesia and Tolerance
|
|
